再鼎医药Zai Lab Limited（ZLAB）2022年20-F年度报告「NASDAQ」（英文版）（154页）.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549_FORM 10-K_(Mark One)x Annual Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934For the fiscal year ended:December 31,2024Or o Transition Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act

2、of 1934 For the transition period from to Commission file number:001-38205_ZAI LAB LIMITED(Exact Name of Registrant as Specified in its Charter)_Cayman Islands98-1144595(State or Other Jurisdiction ofIncorporation or Organization)(I.R.S.EmployerIdentification No.)4560 Jinke RoadBldg.1,4th Floor Pudo

3、ngShanghai,China201210314 Main Street4th Floor,Suite 100Cambridge,MA,USA02142(Address of Principal Executive Offices)(Zip Code)+86 21 6163 2588+1 857 706 2604(Registrants Telephone Number,Including Area Code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(

4、s)Name of each exchange on which registeredAmerican Depositary Shares,each representing 10 Ordinary Shares,par value$0.000006 per shareZLABThe Nasdaq Global MarketOrdinary Shares,par value$0.000006 per share*9688The Stock Exchange of Hong Kong Limited_*Included in connection with the registration of

5、 the American Depositary Shares with the Securities and Exchange Commission.The ordinary shares are not registered or listed for trading in the United States but are listed for trading on the Stock Exchange of Hong Kong Limited.Securities registered pursuant to Section 12(g)of the Act:NoneIndicate b

6、y check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes x No oIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes o No xIndicate by check mark whether the registrant:(1)